56 results
Guidelines for Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip
Guidelines for Perioperative ... Management of Antirheumatic ... Medication in Patients ... #management #autoimmune ... #pharmacology #
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Summary of characteristics of Antianginal Drugs

DRUG CLASS, ADVERSE EFFECTS 
 AND DRUG 
INTERACTIONS 

#Antianginal #Medications #Cardiology
#Antianginal #Medications ... #Cardiology #Pharmacology ... #Management #Therapy
Therapy for AL Amyloidosis 2019 
 - Antibodies (Plasma cells) 
 - Proteasome Inhibitors 
 -
Therapy for AL Amyloidosis ... ALAmyloidosis #Therapy ... #Medications #Therapies ... #Pharmacology # ... Management #Classes
Drug Treatment of Anaphylaxis and Allergic Reactions
First-Line Therapy 
 - Epinephrine 
 - Oxygen 
 -
Reactions First-Line Therapy ... Second-Line Therapy ... #Anaphylaxis #Management ... #Pharmacology # ... Table #Medications
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
areas Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
days) Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
mm3 Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
Daliresp (Roflumilast) 
Indication: Reduce risk of COPD exacerbations 
Drug Class: Selective Phosphodiesterase-4 (PDE4) Inhibitor 
GOLD 2019
: - Triple Therapy ... 2019 COPD GOLD guidelines ... the use of this medication ... already on triple therapy ... #Pharmacology #